July 08, 2020

Arbor Pharmaceuticals, LLC et al v. Lupin Limited et al

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. April 19, 2022

    Arbor, Lupin End IP Suit Over Planned Blood Pressure Generic

    A Delaware federal judge has signed off on the joint dismissal of a patent infringement suit brought by Arbor Pharmaceuticals and Takeda Pharmaceutical Co., the makers of blood pressure drug Edarbi, over Lupin Pharmaceuticals' planned generic.


Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS